Skip to Content
MilliporeSigma

Key Documents

View All Documentation

Skip To

S5521

Suxibuzone

Synonym(s):

4-Butyl-4-(hydroxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione hydrogen succinate (ester)

Sign In to View Organizational & Contract Pricing.

About This Item

Empirical Formula (Hill Notation):
C24H26N2O6
CAS Number:
27470-51-5
Molecular Weight:
438.47
UNSPSC Code:
12352202
PubChem Substance ID:
24899658
EC Number:
248-477-6
MDL number:
MFCD00079562

form

solid

SMILES string

CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c2ccccc2)c3ccccc3

InChI

1S/C24H26N2O6/c1-2-3-16-24(17-32-21(29)15-14-20(27)28)22(30)25(18-10-6-4-7-11-18)26(23(24)31)19-12-8-5-9-13-19/h4-13H,2-3,14-17H2,1H3,(H,27,28)

InChI key

ONWXNHPOAGOMTG-UHFFFAOYSA-N

Biochem/physiol Actions

A prodrug of phenylbutazone.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
089F0243

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

[The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione(suxibuzone), antiinflammatory drug. I. Plasma levels and urinary excretion after oral administration of suxibuzone (author's transl)].
T Shindo et al.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 99(12), 1186-1200 (1979-12-01)
[The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione (suxibuzone), antiinflammatory drug. II. The biological fate of suxibuzone (SB) after daily oral administration (author's transl)].
K Taira et al.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 100(3), 272-279 (1980-03-01)
S Yanagi et al.
Cancer letters, 36(1), 11-18 (1987-07-01)
Among phenylbutazone (PZ) and its related compounds, suxibuzone (SUX) caused the most extensive decrease in pyruvate kinase (PK) activity with lower toxicity. Therefore, we studied the effect of SUX on rat hepatocarcinogenesis to confirm our assumption that an agent which
L Monreal et al.
Research in veterinary science, 76(2), 145-149 (2003-12-16)
The objective was to compare the gastrointestinal and general toxicity of suxibuzone (SBZ) to that of phenylbutazone (PBZ) when administered orally in horses. Fifteen healthy horses were allocated to three treatment groups. One group received a high dose of PBZ
Frank M Andrews et al.
Veterinary therapeutics : research in applied veterinary medicine, 10(3), 113-120 (2009-12-30)
Eighteen mature, healthy horses were divided into three groups (six per group) receiving either no treatment, 15 consecutive days of phenylbutazone (PBZ), or 15 consecutive days of suxibuzone (SBZ) at recommended label doses. Horses underwent endoscopy before and after the
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service